Tesamorelin and CJC-1295 are both GHRH analogues acting on the same receptor — which makes their comparison unusually clean: same mechanism class, radically different evidence tiers. Tesamorelin completed Phase 3 trials and holds FDA approval (as Egrifta) for a specific indication; CJC-1295 stopped at early-phase pharmacology studies. The choice between them in a research context is mostly a choice about what kind of evidence you want behind the compound.
| Attribute | Tesamorelin | CJC-1295 |
|---|---|---|
| Class | Stabilised GHRH analogue (trans-3-hexenoyl modification) | Long-acting GHRH analogue (DAC modification) |
| Evidence tier | Completed Phase 3 programme (NEJM 2007 + follow-ups) | Early-phase human pharmacology only (JCEM 2006) |
| Approval | FDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy; not EU-authorised | Never approved anywhere |
| Demonstrated effect | Visceral fat reduction with lean mass preserved (in the trial population) | Elevated GH/IGF-1 levels for days per dose |
| Half-life | Short (minutes–hours); daily dosing in trials | Days (albumin-bound) |
| WADA status | Prohibited | Prohibited |
| In the Body Pharm catalogue | Yes | Yes — combined with Ipamorelin |
Both compounds stimulate the GHRH receptor, raising growth hormone and IGF-1. Tesamorelin took that mechanism through the full clinical machinery: 26-week randomised Phase 3 trials in HIV-associated lipodystrophy showing significant visceral-fat reduction, an FDA review, and an approved label. CJC-1295’s human record is a handful of early pharmacology studies establishing its long half-life and hormone elevation — no outcome trials, no review, no label.
Tesamorelin’s evidence is real but narrow: it comes from HIV patients with abdominal fat accumulation, and its approval covers exactly that. Extrapolating the visceral-fat effect to other populations is a hypothesis, not a demonstrated result — the same caution that applies to CJC-1295’s hormone-level data applies to tesamorelin outside its trial population.
Tesamorelin’s short half-life meant daily dosing in its trials, mirroring the natural pulse; CJC-1295 produces a sustained multi-day elevation from a single exposure. They also differ in pairing conventions: CJC-1295 is almost always studied alongside ipamorelin (the format Body Pharm supplies), while tesamorelin’s literature is standalone.
Tesamorelin, by a wide margin — completed Phase 3 trials and an FDA-approved indication versus early-phase pharmacology studies. The caveat: that evidence is specific to HIV-associated lipodystrophy.
No. Egrifta holds FDA approval in the US for one indication; there is no EMA marketing authorisation. Research-grade tesamorelin sits outside any approved supply chain.
Both are GHRH-receptor analogues, so the core mechanism matches. They differ in molecular stabilisation, half-life (hours vs days), and the depth of evidence behind each.
Only tesamorelin has demonstrated body-composition outcomes in controlled human trials. CJC-1295 has shown hormone-level changes, not trial-verified composition results.
This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.
We use cookies for analytics and marketing to improve your experience. You can accept or reject non-essential cookies. Privacy Policy